Abstract
Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.
Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.
Current Signal Transduction Therapy
Title:Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis
Volume: 10 Issue: 1
Author(s): Ying Wu, Yi Yang, Haishan Wu, Beibei Zhang, Hui Tang, Jingping Zhao and Jindong Chen
Affiliation:
Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.
Abstract: Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.
Export Options
About this article
Cite this article as:
Wu Ying, Yang Yi, Wu Haishan, Zhang Beibei, Tang Hui, Zhao Jingping and Chen Jindong, Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150311000100
DOI https://dx.doi.org/10.2174/1574362410666150311000100 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Interleukin-10: An Anti-Inflammatory and Immunosuppressive Cytokine in the Normal and Pathological Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of Sympathetic Nerve Activity in Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews The Potential of Hydrogen for Improving Mental Disorders
Current Pharmaceutical Design Autophagy Dysfunction and its Link to Alzheimer’s Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neurotoxicity by Synthetic Androgen Steroids: Oxidative Stress, Apoptosis, and Neuropathology: A Review
Current Neuropharmacology Role of Brain NUCB2/nesfatin-1 in the Regulation of Food Intake
Current Pharmaceutical Design Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design Signal Transduction of Steroidogenic Hormones to the Adrenal and Gonadal Mitochondria and the Possibilities for Combating Lipoid Congenital Adrenal Hyperplasia
Current Signal Transduction Therapy Fat Digestion and its Role in Appetite Regulation and Energy Balance -The Importance of Enterostatin and Tetrahydrolipstatin
Current Medicinal Chemistry - Central Nervous System Agents Gynecomastia in Infants, Children, and Adolescents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Therapeutic Approach of Histamine H3 Receptors in Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Potential Therapeutic Targets for Steroid-Resistant Asthma
Current Drug Targets Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence
Current Pharmaceutical Design The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research